Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1991 Apr 26;13(2):45-57.
doi: 10.1007/BF01974981.

Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections

F N Vincent-Ballereau  1 , O N Patey, C Lafaix
Affiliations
Review

Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections

F N Vincent-Ballereau et al. Pharm Weekbl Sci. .

Abstract

Fluconazole is a novel triazole antifungal drug chiefly used in the treatment of opportunistic mycoses in immuno-compromised patients, particularly those with the acquired immuno-deficiency syndrome (AIDS). In comparison with other antifungal drugs, fluconazole has outstanding physical and pharmacokinetic properties, such as an excellent aqueous solubility allowing a parenteral formulation, high bioavailability by the oral route, even distribution throughout the tissues, including the central nervous system and the cerebro-spinal fluid, a long half-life (permitting once daily administration), and low binding to plasma proteins. It is excreted mainly as unchanged drug in the urine. Fluconazole is a broad-spectrum antifungal agent, especially effective against Candida spp., Cryptococcus neoformans and dermatophytes. Its antifungal efficacy was mainly proved by testing in animal models, since there is no relationship between in vitro and in vivo activities. It possesses a low toxicity and it is well-tolerated. Fluconazole is currently marketed for the treatment of oropharyngeal candidiasis in immuno-compromised patients and of atrophic oral candidiasis. Its place in the treatment of opportunistic mycoses in human immuno-deficiency virus-positive patients, in particular cryptococcal meningitis, is still under investigation but is promising.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Antimicrob Agents Chemother. 1988 May;32(5):646-8 - PubMed
    1. J Infect Dis. 1988 Jan;157(1):178-80 - PubMed
    1. J Med Vet Mycol. 1988 Feb;26(1):67-71 - PubMed
    1. Antimicrob Agents Chemother. 1985 May;27(5):832-5 - PubMed
    1. J Infect. 1990 Jul;21(1):55-60 - PubMed

MeSH terms

LinkOut - more resources